A Roman Catholic priest from Illinois pled guilty this week to charges that he conspired to make and distribute gamma hydroxybutyric acid (GHB), also known as the “date-rape” drug. Rev. Jeffrey Windy allegedly had a chemical solvent used to make the drug delivered to St. Patrick’s Church in Sheffield, Illinois where he worked and then made the drug at a friend’s home. GHB can be used as a hallucinogen or as a means to incapacitate people for the purpose of committing sexual assault. Windy now faces up to 20 years in prison and $1 million in fines. He is to be sentenced on August 22.
Windy’s guilty plea came on the same day that an appeals panel rejected an effort to reduce the sentence of Boston pedophile priest, John Geoghan. Geoghan received a 9-10 year sentence for molesting a 10-year old boy in 1991. Lawyers were attempting to reduce the sentence to 2 years with 8 years of probation. Despite this failed attempt, Geoffrey Packard, Geoghan’s attorney, indicated that Geoghan intends to appeal his conviction.
10/7/2015 Study Finds US Gender Wage Gap Persists - Data compiled by the US Census Bureau this week once again demonstrates a gender wage gap, showing that American women who work full-time, year-round jobs on average earn 79 cents for every dollar paid to men. . . .
10/6/2015 Australia Deports Anti-Abortion Extremist Troy Newman - Anti-abortion extremist Troy Newman has been deported from Australia after an appeal to remain in the country failed to convince the High Court.
Newman was scheduled to speak at a 10-day Right To Life Australia event, but was detained in Denver, Colorado after Immigration Minister Peter Dutton cancelled his visa citing as grounds for revocation Newman's prior history of promoting violence against abortion providers and their patients. . . .
10/6/2015 Sheryl Sandberg Releases Women In the Workplace Study - Sheryl Sandberg, COO of Facebook and the founder of Lean In has launched Women In The Workplace, a study that looks at the state of women in corporate America.
The study, which was released last week, is an ongoing partnership between Lean In and McKinsey & Company. . . .